Department of Removable Prosthodontics, School of Dental Medicine, University of Zagreb, Gundulićeva 5, 10 000, Zagreb, Croatia.
Department of Dentistry, University Clinical Center Zagreb, Zagreb, Croatia.
Sci Rep. 2020 Jul 3;10(1):10981. doi: 10.1038/s41598-020-67383-x.
Temporomandibular disorders (TMD), when progress to a chronic state, might contribute to psychosocial or psychological distress. This study aimed to evaluate the effect of stabilization splint (SS) therapy on pain, pain-related disability and psychological traits of chronic TMD patients, as well as to assess selected oxidative stress (OS) biomarkers during 6-month treatment and associate them with the symptoms of anxiety and depression. Thirty-four participants were randomly assigned into two treatment groups [SS and placebo splint (PS)]. Primary outcomes were pain intensity and pain-related disability while secondary outcomes included depressive and anxiety symptoms. The influence of the treatment type was analyzed with regards to the levels of OS biomarkers in saliva. Participants treated with SS demonstrated significantly greater improvement in pain-related disability (Pain-free mouth opening: p = 0.018, η = 0.166; Number of disability days: p = 0.023, η = 0.155) and greater reduction of depressive symptoms scores (p = 0.007, η = 0.207). When compared to the PS group, participants in the SS group showed a significant reduction of oxidant/antioxidant ratio (p = 0.018, η = 0.167) at a 3-month follow-up. A stabilization splint provides advantages over PS in the treatment of depressive symptoms and pain-related disability. Furthermore, clinical success in terms of reduction of depressive symptoms, which correlates with the reduction of oxidative stress markers in the SS group, indicates that oxidative stress is related to psychological factors in chronic TMD patients.
颞下颌关节紊乱(TMD)发展为慢性状态时,可能会导致心理社会或心理困扰。本研究旨在评估稳定夹板(SS)治疗对慢性 TMD 患者疼痛、疼痛相关残疾和心理特征的影响,以及在 6 个月治疗期间评估选定的氧化应激(OS)生物标志物,并将其与焦虑和抑郁症状相关联。34 名参与者被随机分配到两个治疗组[SS 和安慰剂夹板(PS)]。主要结局是疼痛强度和疼痛相关残疾,次要结局包括抑郁和焦虑症状。分析了治疗类型对唾液中 OS 生物标志物水平的影响。接受 SS 治疗的患者在疼痛相关残疾方面(张口无痛:p = 0.018,η = 0.166;残疾天数:p = 0.023,η = 0.155)和抑郁症状评分的降低(p = 0.007,η = 0.207)方面有显著改善。与 PS 组相比,SS 组患者在 3 个月随访时氧化剂/抗氧化剂比值显著降低(p = 0.018,η = 0.167)。与 PS 相比,SS 在治疗抑郁症状和疼痛相关残疾方面具有优势。此外,从减少抑郁症状的临床效果来看,这与 SS 组氧化应激标志物的减少相关,表明氧化应激与慢性 TMD 患者的心理因素有关。